Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received a new Australian composition of matter patent for its Bisphosphocin® antimicrobial compounds, covering uses in infections including complicated urinary tract and pulmonary infections.

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received a new Australian composition of matter patent for its Bisphosphocin® antimicrobial compounds, covering uses in infections including complicated urinary tract and pulmonary infections.

The patent, issued March 5, 2026, expands a portfolio of 72 granted and 29 pending patents worldwide, supporting development against antimicrobial resistance.

Positive

• New Australian composition of matter patent for Bisphosphocin® compounds issued March 5, 2026
• IP portfolio now totals 72 granted and 29 pending patents globally
• Patent coverage includes complicated urinary tract and pulmonary infections
• Protection spans major regions including US, Europe, China, India, Japan, and Australia

Negative

• None.

Argus Jun 22 session

-5.46% close to close Open Argus

Details

News Market Reaction – LABT

In the Jun 22 session, LABT declined 5.46%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.5% in the session following this news. A negative reaction despite positive news ...

Analysis

The stock moved -5.5% in the session following this news. A negative reaction despite positive news fits LABT’s history of sharp selloffs after favorable updates. New Australian composition-of-matter protection lifts IP strength, but recent losses, low cash and resale overhang may still dominate sentiment.

Key Figures

Granted patents: 72 granted patents Pending patents: 29 pending patents Net loss: $923,291 +5 more

Granted patents

72 granted patents

Global intellectual property portfolio across multiple regions

Pending patents

29 pending patents

Global intellectual property portfolio across multiple regions

Net loss

$923,291

Quarter ended March 31, 2026 (Form 10-Q)

Cash and cash equivalents

$11,709

As of March 31, 2026 (Form 10-Q)

Total liabilities

$3,037,991

As of March 31, 2026 (prospectus/10-Q data)

Series C gross proceeds

$7.5M

Private Series C Convertible Preferred Stock financing in April 2026

Series C net proceeds

$6.8M

Private Series C Convertible Preferred Stock financing in April 2026

Registered resale shares

9,647,726 shares

Common stock registered for resale on Form 424B4

Historical Context

5 past events · Latest: Jun 16

5 events

1. Jun 16

   Investor conference

   24h Move

   -0.7%

   Upcoming virtual investor forum presentation and Nu-3 Phase 2 development overview.

2. May 27

   IP expansion

   24h Move

   +3.0%

   New patents expanding Nu-3 gel and Bisphosphocin platform protection globally.

3. May 18

   Formulation progress

   24h Move

   -36.6%

   Positive formulation, stability and manufacturing data enabling planned Phase 2 trial.

4. May 12

   CRO agreement

   24h Move

   +1.9%

   PERI engaged as CRO to run Nu-3 Phase 2 clinical program in iDFU.

5. May 01

   AMR data

   24h Move

   +28.9%

   Strong antimicrobial resistance profile data for Nu-3 against key resistant pathogens.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

composition of matter patent, broad-spectrum antimicrobials, antimicrobial resistance, intellectual property portfolio

4 terms

composition of matter patent regulatory

"Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds"

A composition of matter patent is a legal right that protects a specific chemical, molecule, material or formulated mixture—think of it as locking down a unique recipe for a substance. For investors it matters because the patent can give a company exclusive control to make, sell, or license that substance, creating a potential source of revenue and a competitive barrier similar to owning the only map to a valuable resource.

broad-spectrum antimicrobials medical

"a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases"

Broad-spectrum antimicrobials are drugs that act against a wide variety of disease-causing microbes rather than targeting a single species—think of a Swiss Army knife that works on many different problems. For investors, they matter because they can reach larger markets and be used empirically before exact diagnoses, but they also carry regulatory, resistance and stewardship risks that affect long-term sales and valuation.

antimicrobial resistance medical

"Antimicrobial resistance (AMR) is a global crisis that is directly responsible"

Antimicrobial resistance is when microbes such as bacteria, viruses or fungi evolve so that medicines meant to kill them no longer work — like a lock changing so the old key no longer fits. For investors, this increases demand and cost for new treatments, prolongs hospital stays, prompts tougher regulation and can shrink sales of once-effective drugs, affecting pharmaceutical revenues, R&D spending and broader healthcare risk.

intellectual property portfolio financial

"adds to our international intellectual property portfolio covering composition of matter patents"

A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New patent enhances global IP footprint and pipeline expansion opportunities

SARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin^® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.

The patent, titled, "Antimicrobial Compounds, Compositions, and Uses Thereof," was issued March 5, 2026, by IP Australia. Lakewood-Amedex Biotherapeutics' intellectual property portfolio is currently comprised of 72 granted patents and 29 pending patents in multiple countries and regions, including the United States, the European Patent Office, China, India, Japan, Mexico, Hong Kong, Republic of Korea, Brazil, United Kingdom, New Zealand, and Australia.

"This newly issued patent adds to our international intellectual property portfolio covering composition of matter patents for the Bisphosphocin^® class of compounds," said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "Antimicrobial resistance (AMR) is a global crisis that is directly responsible for more than a six million deaths annually. As we work to deliver innovative antimicrobial solutions designed to tackle the challenges of AMR, our substantial IP foundation enhances our ability to bring solutions to the millions of patients in need, while potentially generating value for our shareholders."

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-secures-composition-of-matter-patent-protecting-new-bisphosphocin-compounds-being-developed-for-high-need-antimicrobial-infections-302805728.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What patent did Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announce on June 22, 2026?

Lakewood-Amedex Biotherapeutics announced a new Australian patent titled “Antimicrobial Compounds, Compositions, and Uses Thereof.” According to Lakewood-Amedex Biotherapeutics, it protects Bisphosphocin® antimicrobial compounds being developed for a range of serious infections, including complicated urinary tract and pulmonary infections.

How does the new Australian patent affect LABT’s intellectual property portfolio?

The new Australian patent expands LABT’s global composition of matter protection for Bisphosphocin® compounds. According to Lakewood-Amedex Biotherapeutics, its portfolio now includes 72 granted patents and 29 pending patents across multiple key markets, strengthening long-term protection for its antimicrobial pipeline.

Which infections are targeted by Lakewood-Amedex Biotherapeutics’ Bisphosphocin® compounds under the new patent?

The patented Bisphosphocin® compounds are being explored for multiple antimicrobial infections. According to Lakewood-Amedex Biotherapeutics, these include complicated urinary tract infections and pulmonary infections, areas of high unmet medical need linked to growing antimicrobial resistance worldwide.

In which countries and regions does LABT hold patents for Bisphosphocin® as of June 2026?

LABT reports granted and pending Bisphosphocin® patents in the US, European Patent Office region, China, India, Japan, Mexico, Hong Kong, Republic of Korea, Brazil, United Kingdom, New Zealand, and Australia. According to Lakewood-Amedex Biotherapeutics, this broad coverage supports its global development plans.

How is Lakewood-Amedex Biotherapeutics positioning Bisphosphocin® against antimicrobial resistance (AMR)?

Lakewood-Amedex Biotherapeutics is advancing Bisphosphocin® as potent, fast-acting, broad-spectrum antimicrobials. According to Lakewood-Amedex Biotherapeutics, AMR is directly responsible for more than six million deaths annually, and its growing IP estate aims to support delivering innovative treatments and potential value for shareholders.

What stage of development is Lakewood-Amedex Biotherapeutics at with its Bisphosphocin® platform?

Lakewood-Amedex Biotherapeutics describes itself as a clinical-stage biotechnology company. According to Lakewood-Amedex Biotherapeutics, it is advancing Bisphosphocin® compounds as a novel class of broad-spectrum antimicrobials for infectious diseases, supported by an expanding international patent portfolio.